Abstract
Studies of various established human bladder and renal carcinoma cell lines cultured in vitro demonstrated the presence of specific, saturable, high affinity binding sites for 125I-labeled human interferon βser (IFN-βser). This recombinant produced interferon labeled with approximately one atom of 125I/molecule of IFN expressed minimal or no loss of antiviral activity. A single class of binding sites (1000–2000/cell) with an affinity constant of 1010–1011 L/M was measured at 4°C for cells exhibiting widely different sensitivity to the antiproliferative effect of IFN-βser. Major fluctuations in the binding of 125I-labeled IFN-βser to cellular receptors were observed during in vitro proliferation of four of five cell lines examined. A significant decrease (P < 0.001) in specific binding was observed 48 h after cultures were established. Cell cycle analysis suggested that within the first 24 h and in the very late log and stationary phase of growth of ACHN (human renal carcinoma) cells, variations in the binding of 125I-labeled IFN-βser were partially attributable to binding fluctuations during the mitotic cycle. The 2- to 3-fold decline 24 h following plating of ACHN cells corresponded to a 70% decrease in the number of cells in G0-G1. T24 (human transitional cell carcinoma) and ACHN cells, synchronized by serum starvation, demonstrated increased binding of 125I-labeled IFN-βser 4–16 h following serum replenishment. This increase in receptor binding occurred prior to the onset of DNA and protein synthesis and was followed by a decline immediately prior to cell division. Binding site analysis indicated that the increased binding prior to DNA synthesis was due to a 5- to 6-fold increase in receptor affinity for the radiolabeled ligand. After an initial 40% decline in receptors per cell following serum stimulation, receptor concentration remained essentially unchanged. Induction of 2′,5′-oligoadenylate synthetase in ACHN cells and antiproliferative activity in RT112, RT4, T24 (human transitional cell carcinoma), and ACHN cells by IFN-βser decreased significantly 48 h following plating. These changes in the biological activity of this interferon corresponded to growth related fluctuations in the IFN-βser binding.
Footnotes
-
↵1 Supported by the Triton Biosciences Interferon Program (Alameda, CA).
-
↵2 Recipient of a NIH National Research Service Award Supported Postdoctoral Fellowship.
-
↵3 American Cancer Society Professor of Clinical Oncology. To whom requests for reprints should be addressed.
- Received October 27, 1986.
- Revision received May 27, 1987.
- Accepted June 3, 1987.
- ©1987 American Association for Cancer Research.